Bo Cumbo, president and CEO of Solid Biosciences (SLDB) commented, “The interim INSPIRE DUCHENNE data reported today strengthens our confidence in SGT-003’s therapeutic potential. From strong observed biological correlations of SGT-003 microdystrophin expression levels with properly localized restoration of key components of the dystrophin-associated protein complex to early evidence of cardiac function normalization, we are observing a clear and cascading effect in the human body, suggesting a coordinated, systemic response to treatment. We believe these interim data represent one of the most thorough early analyses of any Duchenne gene therapy to date. The quality and concurrence of these interim findings reinforce our conviction in SGT-003’s potential to translate molecular impact into meaningful clinical outcomes.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences Advances Gene Therapy Study for Friedreich’s Ataxia
- Solid Biosciences Advances Duchenne Gene Therapy with SGT-003 Study
- Solid Biosciences Advances Gene Therapy Study for Rare Heart Condition
- Solid Biosciences’ Phase 3 Gene Therapy Study for Duchenne Muscular Dystrophy: A Market Perspective
- Solid Biosciences: Strategic Collaborations and Regulatory Progress Drive Buy Rating